Smolen JS, et al. - This study involved examination of moderately active rheumatoid arthritis (RA) who received full-dose combination etanercept plus methotrexate induction therapy followed by reduced-dose etanercept or etanercept withdrawal. The goal was to analyze characteristics that predict remission induction and subsequent loss of remission in this population. Findings suggested that with combination etanercept and methotrexate induction therapy, attainment of remission was most likely in patients who were younger and had lower body mass index, lower Health Assessment Questionnaire (HAQ), and lower disease activity at baseline. Additionally, loss of remission across all treatment arms was most likely to be seen in patients who failed to achieve sustained remission with induction therapy and those with worse disease activity and patient-reported outcomes at early time points after initiating maintenance therapy with a full-dose or reduced-dose etanercept-methotrexate regimen or methotrexate monotherapy.